EA201890828A1 - Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин - Google Patents

Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин

Info

Publication number
EA201890828A1
EA201890828A1 EA201890828A EA201890828A EA201890828A1 EA 201890828 A1 EA201890828 A1 EA 201890828A1 EA 201890828 A EA201890828 A EA 201890828A EA 201890828 A EA201890828 A EA 201890828A EA 201890828 A1 EA201890828 A1 EA 201890828A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active compound
high dose
mesalazin
tablet
optimized
Prior art date
Application number
EA201890828A
Other languages
English (en)
Inventor
Рудольф Вильхельм
Маркус Прёльс
Роланд Грайнвальд
Танжу Наджак
Original Assignee
Др. Фальк Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Фальк Фарма Гмбх filed Critical Др. Фальк Фарма Гмбх
Publication of EA201890828A1 publication Critical patent/EA201890828A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Настоящее изобретение относится к пероральной энтеросолюбильной таблетке с высокой дозой активного соединения, содержащей в качестве активного соединения месалазин, а также к ее применению.
EA201890828A 2015-10-30 2016-10-21 Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин EA201890828A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15192269.7A EP3162362A1 (de) 2015-10-30 2015-10-30 Optimierte mesalazinhaltige hochdosistablette
PCT/EP2016/075427 WO2017072050A1 (de) 2015-10-30 2016-10-21 Optimierte mesalazinhaltige hochdosistablette

Publications (1)

Publication Number Publication Date
EA201890828A1 true EA201890828A1 (ru) 2018-11-30

Family

ID=54476727

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890828A EA201890828A1 (ru) 2015-10-30 2016-10-21 Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин

Country Status (21)

Country Link
US (1) US11135159B2 (ru)
EP (2) EP3162362A1 (ru)
JP (1) JP6872135B2 (ru)
KR (1) KR20180077246A (ru)
CN (2) CN117180218A (ru)
AU (1) AU2016347352B2 (ru)
CA (1) CA3001435A1 (ru)
CY (1) CY1122473T1 (ru)
DK (1) DK3368017T3 (ru)
EA (1) EA201890828A1 (ru)
ES (1) ES2761319T3 (ru)
HK (1) HK1255193A1 (ru)
HR (1) HRP20192184T1 (ru)
HU (1) HUE046593T2 (ru)
LT (1) LT3368017T (ru)
MX (1) MX2018005358A (ru)
PL (1) PL3368017T3 (ru)
PT (1) PT3368017T (ru)
RS (1) RS59748B1 (ru)
SI (1) SI3368017T1 (ru)
WO (1) WO2017072050A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162293A1 (it) * 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
TR201722039A2 (tr) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mesalazi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3662895A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
DK1146862T3 (da) 1999-01-29 2003-07-21 Disphar Int Bv Farmaceutiske sammensætninger
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
CA2444814C (en) * 2001-10-24 2009-06-09 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
MXPA04004747A (es) * 2001-11-23 2004-08-02 Procter & Gamble Forma de dosificacion farmaceutica con multiples recubrimientos.
EP1519717B1 (en) * 2002-07-05 2010-09-29 Temrel Limited Controlled release composition
JP2007523664A (ja) 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ 医薬組成物用サシェ
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
WO2009047802A2 (en) * 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
CN105363034A (zh) * 2008-05-23 2016-03-02 香港大学 治疗流感的联合疗法
WO2011045775A1 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited A delayed release pharmaceutical composition of mesalamine
EP2425826A1 (en) * 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
ES2821766T3 (es) * 2013-02-22 2021-04-27 Zeria Pharm Co Ltd Comprimido con recubrimiento entérico
UA117260C2 (uk) * 2013-10-29 2018-07-10 Тиллоттс Фарма АГ Лікарський препарат з відстроченим вивільненням
IN2014MU00097A (ru) * 2014-01-10 2015-08-21 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
HK1255193A1 (zh) 2019-08-09
KR20180077246A (ko) 2018-07-06
WO2017072050A1 (de) 2017-05-04
EP3368017B1 (de) 2019-11-06
EP3162362A1 (de) 2017-05-03
DK3368017T3 (da) 2019-12-16
HUE046593T2 (hu) 2020-03-30
PT3368017T (pt) 2020-01-06
CN108348472A (zh) 2018-07-31
EP3368017A1 (de) 2018-09-05
JP2018531960A (ja) 2018-11-01
LT3368017T (lt) 2020-01-27
PL3368017T3 (pl) 2020-04-30
MX2018005358A (es) 2018-06-06
US20180311155A1 (en) 2018-11-01
AU2016347352A1 (en) 2018-05-10
US11135159B2 (en) 2021-10-05
CN117180218A (zh) 2023-12-08
ES2761319T3 (es) 2020-05-19
CY1122473T1 (el) 2021-01-27
JP6872135B2 (ja) 2021-05-19
RS59748B1 (sr) 2020-02-28
HRP20192184T1 (hr) 2020-03-06
CA3001435A1 (en) 2017-05-04
AU2016347352B2 (en) 2021-09-09
SI3368017T1 (sl) 2020-01-31

Similar Documents

Publication Publication Date Title
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
MX2018006148A (es) Inhibidores de cxcr2.
EA201400753A1 (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
EA201792021A1 (ru) Ингибитор jak
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
GT201500247A (es) Imidazopiridazinas sustituidas
EA201791219A1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
EA201791174A1 (ru) Антимикотическое соединение
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
MX2017007377A (es) Compuestos organicos.
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.